Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: A US managed care study

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 1987-2000

  Foody, Joanne M ^a,f   Joyce, Amie T ^b   Rudolph, Amy E ^c   Liu, Larry Z ^c,d   Benner, Joshua S ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b IMS   (United States)

^c PFIZER INC   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e IQVIA   (United States)

^f Brigham and Women's/Faulkner Hospitals   (United States)

Author keywords

Adherence; Hydroxymethylglutaryl CoA reductase inhibitors; Hyperlipidemia; Persistence; Statins

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DATA BASE; DEMOGRAPHY; DRUG UTILIZATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PRIMARY PREVENTION; RETROSPECTIVE STUDY; SECONDARY PREVENTION; TREATMENT WITHDRAWAL; UNITED STATES;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; DRUG UTILIZATION REVIEW; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN; SURVIVAL ANALYSIS; UNITED STATES;

EID: 47949124494     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802203279     Document Type: Article

References (60)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 2005;352:1425-35
3. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia [West of Scotland Coronary Prevention Study Group]. New Engl J Med 1995;333:1301-7
5. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT - LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS [Air Force/Texas Coronary Atherosclerosis Prevention Study]. J Am Med Assoc 1998;279:1615-22
7. Anon. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
8. Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. Br Med J 2005;330:821
9. Mehta JL, Bursac Z, Hauer-Jensen M, et al. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. Am J Cardiol 2006;98:923-8
10. Fintel D, Joyce A, Mackell J, et al. Reduced mortality rates after intensive statin therapy in managed-care patients. Value Health 2007;10:161-9
11. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 2004;44:1772-9
12. Colhoun HM, Betteridge DJ, Durrington PN, et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005;48:2482-5
13. Sever PS, Poulter NR, Dahlöf B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm: extended observations 2 years after trial closure. Eur Heart J 2008;29:499-508
14. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-45
15. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. J Am Med Assoc 2002;288:455-61
16. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9
17. Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005;59:564-73
18. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. J Am Med Assoc 2002;288:462-7
19. Donovan JL. Patient decision making. The missing ingredient in compliance research. Int J Technol Assess Health Care 1995;11:443-55
20. Blackburn DF, Dobson RT, Blackburn JL, et al. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 2005;25:1035-43
21. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-7
22. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-41
23. Ho PM, Magid DJ, Masoudi FA, et al. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 2006;6:48
24. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-11
25. LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2000;9:1169-75
26. Luepker RV. Patient adherence: a 'risk factor' for cardiovascular disease. Heart Dis Stroke 1993;2:418-21
27. Benner JS, Pollack MF, Smith TW, et al. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005;62:1468-75
28. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q 1988;15:175-83
29. Richardson MA, Simons-Morton B, Annegers JF. Effect of perceived barriers on compliance with antihypertensive medication. Health Educ Q 1993;20:489-503
30. Anon. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
31. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
32. Parris ES, Lawrence DB, Mohn LA, et al. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-9
33. PharMetrics, a Unit of IMS. 2008. Available at: http://www.imshealth.com/ web/channel/0,3147,77141581_63872702_78513316,00.html [last accessed April 22 2008]
34. Anon. International classification of diseases, ninth revision (ICD-9), National Center for Health Statistics: Centers for Disease Control; 2008
35. Anon. Current procedural terminology, 1st ed. American Medical Association: Thomas Delmar Learning; 2006
36. Health care common procedural coding system [HCPCS], the Centers for Medicare & Medicaid Services, Department of Health and Human Services; 2008
37. National drug code, US Food and Drug Administration, Department of Health and Human Services; 2008. Available at: http://www.fda.gov/cder/ndc [last accessed March 2008]
38. Fleiss JL, Levin B, Myunghee CP. Statistical methods for rates and proportions, 3rd ed. Hoboken (NJ): Wiley-Interscience; 2003
39. Hollander M, Wolfe DA. Nonparametric statistical methods, 2nd ed. Hoboken (NJ): Wiley-Interscience; 1999
40. Lee ET. Statistical methods for survival data analysis, 2nd ed. New York: John Wiley & Sons, Inc.; 1992
41. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52
42. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, et al. Long term persistence with statin treatment in daily medical practice. Heart (British Cardiac Society) 2004;90:1065-6
43. Foody JM, Joyce AT, Rudolph AE, et al. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther 2008;30:195-205
44. Phillips B, Roberts C, Rudolph AE, et al. Switching statins: the impact on patient outcomes. Br J Cardiol 2007;14:280-5
45. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-52
46. Bybee KA, Wright RS, Williams BA, et al. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. Am J Cardiol 2001;87:771-4, A7
47. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001;357:1063-8
48. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. J Am Med Assoc 2001;285:430-6
49. Colivicchi F, Bassi A, Santini M, et al. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007;38:2652-7
50. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007;69:904-10
51. Monane M, Matthias DM, Nagle BA, et al. Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking the physician, pharmacist, and computer. J Am Med Assoc 1998;280:1249-52
52. Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998;12:7-15
53. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. J Am Med Assoc 1998;279:1458-62
54. Sever PS, Poulter NR, Dahlöf B, et al. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT - LLA). Am J Cardiol 2005;96:39F-44F
55. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
56. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New Engl J Med 2007;357:1477-86
57. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. J Am Med Assoc 2001;285:1711-8
58. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med 2004;350:1495-504
59. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-97
60. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3:417-26